Lumida
/INSM
⌘K
Insmed Inc

Insmed Inc

INSM
$129.41USD+1.67%+2.13 today

MARKET CAP

28.3B

P/E (TTM)

FWD P/E

DAY RANGE

$127 – $130

52W RANGE

$90
$213

AI Summary

Stalk
Buy NowMedium

INSM exhibits a medium-term bullish posture driven by a Bullish Pivot Point and successive Higher Highs & Higher Lows patterns, with price trading above rising 9/20 EMAs. Short-term conditions favor immediate participation as price resolves consolidation into a breakout zone. Execution should occur now, targeting continuation participation while remaining mindful of the long-term downtrend signaled by a declining 200 DMA.

  • Q2 Brinsupri revenue $309.2M up 49% sequential affirms strong demand
  • Raised full-year 2026 Brinsupri guidance to $1.25–$1.4B on robust uptake
  • Negative earnings yield and low book-to-price ratio suggest overvaluation
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$188.5M$245.4M$305.2M$363.7M$606.4M
YoY %+14.6%+30.2%+24.4%+19.2%+66.7%
P / Sales16.2x9.6x13.8x31.1x57.1x
EV / Sales16.8x11.6x17.6x34.4x58.8x
Gross Profit, Adj.$144.3M$190.2M$239.6M$278.0M$483.5M
YoY %+15.9%+31.8%+26.0%+16.0%+73.9%
Margin %76.6%77.5%78.5%76.4%79.7%
EV / Gross Profit22.0x15.0x22.5x45.0x73.7x
EBITDA, Adj.$-352.5M$-465.8M$-699.0M$-867.2M$-1.2B
YoY %-41.0%-32.2%-50.1%-24.1%-41.9%
Margin %-187.0%-189.9%-229.0%-238.4%-202.9%
EV / EBITDA-9.0x-6.1x-7.7x-14.4x-29.0x
EBIT$-375.1M$-457.3M$-709.6M$-878.3M$-1.2B
YoY %-41.4%-21.9%-55.2%-23.8%-42.0%
Margin %-199.0%-186.4%-232.5%-241.5%-205.6%
EV / EBIT-8.5x-6.2x-7.6x-14.2x-28.6x
Net Income$-434.7M$-481.5M$-749.6M$-913.8M$-1.3B
YoY %-47.8%-10.8%-55.7%-21.9%-39.7%
Net Margin-230.6%-196.3%-245.6%-251.2%-210.5%
EPS (GAAP)-$3.88-$3.91-$5.34-$5.57-$6.42
YoY %-28.9%-0.8%-36.6%-4.3%-15.3%